CoChat
Sign Up
Cited by 637

The DOI matches its Crossref record, with a small difference in title or year; 2 of the 2 references it cites were found in a registry or an index.

Diagnosis and Evaluation of Hypertrophic Cardiomyopathy

Maron, Barry J., Desai, Milind Y., Nishimura, Rick A., Spirito, Paolo, Rakowski, Harry, Towbin, Jeffrey A., Rowin, Ethan J., Maron, Martin S., Sherrid, Mark V.·2022·Journal of the American College of Cardiology
DOI 10.1016/j.jacc.2021.12.002
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2021.12.002

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Figures

Image 1
CC-BY-NC-ND · From the PDF
Image 2
CC-BY-NC-ND · From the PDF
Image 3
CC-BY-NC-ND · From the PDF
(A and B) Absence of systolic anterior motion and out fl ow obstruction; and (C and D) out fl ow gradient under resting conditions. (C) Stress (exercise) induced obstruction to left ventricular (LV) out fl ow due to anterior mitral lea fl et contact with ventricular septum (VS) (double arrows) , (D) producing a continuous-wave Doppler estimate of a 100-mm Hg gradient (5-m/s jet). (E to G) Transesophageal images showing (E) systolic anterior motion and septal contact (arrow) typically associated with (F) a secondary posteriorly directed mitral regurgitation jet (double arrows) . (G) In another patient, an anterior and centrally directed jet from intrinsic mitral valve pathology requiring operative repair (triple arrows) . Reproduced with permission from Rowin et al. 4 Ao ¼ aorta; LA ¼ left atrium.
(A and B) Absence of systolic anterior motion and out fl ow obstruction; and (C and D) out fl ow gradient under resting conditions. (C) Stress (exercise) induced obstruction to left ventricular (LV) out fl ow due to anterior mitral lea fl et contact with ventricular septum (VS) (double arrows) , (D) producing a continuous-wave Doppler estimate of a 100-mm Hg gradient (5-m/s jet). (E to G) Transesophageal images showing (E) systolic anterior motion and septal contact (arrow) typically associated with (F) a secondary posteriorly directed mitral regurgitation jet (double arrows) . (G) In another patient, an anterior and centrally directed jet from intrinsic mitral valve pathology requiring operative repair (triple arrows) . Reproduced with permission from Rowin et al. 4 Ao ¼ aorta; LA ¼ left atrium.CC-BY-NC-ND · From the PDF
(A) Changes to left ventricular (LV) out fl ow tract gradient from basal (rest) to immediately after physiologic (exercise) provocation in 200 hypertrophic cardiomyopathy patients. 72 Each exercised patient is depicted by a line connecting the 2 gradient measurements. Ø ¼ group means. Reproduced with permission from Maron et al. 72 (B) Relation of gradients at rest or with exercise provocation (while NYHA functional class I/II) to subsequent progressive heart failure (New York Heart Association [NYHA] functional class III/IV).
(A) Changes to left ventricular (LV) out fl ow tract gradient from basal (rest) to immediately after physiologic (exercise) provocation in 200 hypertrophic cardiomyopathy patients. 72 Each exercised patient is depicted by a line connecting the 2 gradient measurements. Ø ¼ group means. Reproduced with permission from Maron et al. 72 (B) Relation of gradients at rest or with exercise provocation (while NYHA functional class I/II) to subsequent progressive heart failure (New York Heart Association [NYHA] functional class III/IV).CC-BY-NC-ND · From the PDF
Image 6
CC-BY-NC-ND · From the PDF
Image 7
CC-BY-NC-ND · From the PDF
Image 8
CC-BY-NC-ND · From the PDF
ACC ¼ American College of Cardiology; AHA ¼ American Heart Association; ESC ¼ European Society of Cardiology; HCM ¼ hypertrophic cardiomyopathy; SAM ¼ systolic anterior motion.
ACC ¼ American College of Cardiology; AHA ¼ American Heart Association; ESC ¼ European Society of Cardiology; HCM ¼ hypertrophic cardiomyopathy; SAM ¼ systolic anterior motion.CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 75

  1. Maron, 2018, Clinical course and management of hypertrophic cardiomyopathy, N Engl J Med, 379, 655, 10.1056/NEJMra1710575 · DOI · Paper page
  2. Maron, 2016, How hypertrophic cardiomyopathy became a contemporary treatable genetic disease with low mortality: shaped by 50 years of clinical research and practice, JAMA Cardiol, 1, 98, 10.1001/jamacardio.2015.0354 · DOI · Paper page
  3. Maron, 2016, The remarkable 50 years of imaging in HCM and how it has changed diagnosis and management: from M-mode echocardiography to CMR, J Am Coll Cardiol Img, 9, 858, 10.1016/j.jcmg.2016.05.003 · DOI
  4. Rowin, 2020, The hypertrophic cardiomyopathy phenotype viewed through the prism of multimodality imaging: clinical and etiologic implications, J Am Coll Cardiol Img, 13, 2002, 10.1016/j.jcmg.2019.09.020 · DOI
  5. Maron, 2009, Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance, J Am Coll Cardiol, 54, 220, 10.1016/j.jacc.2009.05.006 · DOI
  6. Ommen, 2020, 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy, J Am Coll Cardiol, 76, e159, 10.1016/j.jacc.2020.08.045 · DOI · Paper page
  7. Gersh, 2011, J Am Coll Cardiol, 58, e212, 10.1016/j.jacc.2011.06.011 · DOI · Paper page
  8. Elliott, 2014, 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC), Eur Heart J, 35, 2733, 10.1093/eurheartj/ehu284 · DOI · Paper page
  9. Rowin, 2017, Interaction of adverse disease-related pathways in hypertrophic cardiomyopathy, Am J Cardiol, 120, 2256, 10.1016/j.amjcard.2017.08.048 · DOI
  10. Maron, 1999, Clinical course of hypertrophic cardiomyopathy in a regional United States cohort, JAMA, 281, 650, 10.1001/jama.281.7.650 · DOI
  11. Maron, 2012, Evolution of hypertrophic cardiomyopathy to a contemporary treatable disease, Circulation, 126, 1640, 10.1161/CIRCULATIONAHA.112.123174 · DOI
  12. Rowin, 2020, Hypertrophic cardiomyopathy in “Real World” community cardiology practice, Am J Cardiol, 125, 1398, 10.1016/j.amjcard.2020.01.040 · DOI
  13. Kotkar, 2017, Hypertrophic obstructive cardiomyopathy: the Mayo Clinic experience, Ann Cardiothorac Surg, 6, 329, 10.21037/acs.2017.07.03 · DOI
  14. Ommen, 2005, Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy, J Am Coll Cardiol, 46, 470, 10.1016/j.jacc.2005.02.090 · DOI
  15. Desai, 2013, Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction, Circulation, 128, 209, 10.1161/CIRCULATIONAHA.112.000849 · DOI · Paper page
  16. Hodges, 2019, Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center, J Cardiovasc Surg, 157, 2289
  17. Maron, 2018, Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy, J Am Coll Cardiol HF, 6, 353
  18. Maron, 2019, Enhanced American College Cardiology/American Heart Association strategy for prevention of sudden cardiac death in high risk patients with hypertrophic cardiomyopathy, JAMA Cardiol, 4, 644, 10.1001/jamacardio.2019.1391 · DOI
  19. Maron, 2021, Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: twenty years with the implantable cardioverter-defibrillator, Heart Rhythm, 18, 1012, 10.1016/j.hrthm.2021.01.019 · DOI
  20. Rowin, 2017, Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy, Circulation, 136, 2420, 10.1161/CIRCULATIONAHA.117.029267 · DOI · Paper page
  21. Maron, 2016, Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy, J Am Coll Cardiol, 67, 1399, 10.1016/j.jacc.2016.01.023 · DOI
  22. Rowin, 2020, Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction, J Am Coll Cardiol, 75, 3033, 10.1016/j.jacc.2020.04.045 · DOI
  23. Maron, 2003, American College of Cardiology/European Society of Cardiology clinical expert consensus document of hypertrophic cardiomyopathy, J Am Coll Cardiol, 42, 1687, 10.1016/S0735-1097(03)00941-0 · DOI
  24. Rowin, 2018, Clinical spectrum and management implications of left ventricular outflow obstruction with mild ventricular septal thickness in hypertrophic cardiomyopathy, Am J Cardiol, 122, 1409, 10.1016/j.amjcard.2018.06.055 · DOI
  25. Maurizi, 2019, Clinical course and significance of hypertrophic cardiomyoapthy without left ventricular hypertrophy, Circulation, 139, 830, 10.1161/CIRCULATIONAHA.118.037264 · DOI
  26. Norrish, 2019, Development of a novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM Risk-Kids), JAMA Cardiol, 4, 918, 10.1001/jamacardio.2019.2861 · DOI
  27. Maron, 2009, Hypertrophic cardiomyopathy without hypertrophy: an emerging preclinical subgroup composed of genetically affected family members, J Am Coll Cardiol Img, 2, 65, 10.1016/j.jcmg.2008.09.008 · DOI
  28. Rowin, 2017, Role of exercise testing in hypertrophic cardiomyopathy, J Am Coll Cardiol Img, 10, 1374, 10.1016/j.jcmg.2017.07.016 · DOI
  29. Tower-Radar, 2019, Prognostic value of global longitudinal strain in hypertrophic cardiomyopathy: a systematic review of existing literature, J Am Coll Cardiol Img, 12, 1930, 10.1016/j.jcmg.2018.07.016 · DOI
  30. Rowin, 2021, Usefulness of global longitudinal strain to predict heart failure progression in patients with nonobstructive hypertrophic cardiomyopathy, Am J Cardiol, 151, 86, 10.1016/j.amjcard.2021.04.021 · DOI
  31. Maron, 2011, Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy, Circulation, 124, 40, 10.1161/CIRCULATIONAHA.110.985812 · DOI
  32. Olivotto, 2014, Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy, Am J Cardiol, 113, 1394
  33. Massera, 2019, Prevalence of unxplained left ventricular hypertrophy by cardiac magnetic resonance imaging in MESA, J Am Heart Assoc, 8
  34. Chan, 2014, Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy, Circulation, 130, 484, 10.1161/CIRCULATIONAHA.113.007094 · DOI · Paper page
  35. Weng, 2016, Prognostic value of LGE-CMR in HCM: a meta-analysis, J Am Coll Cardiol Img, 9, 1392, 10.1016/j.jcmg.2016.02.031 · DOI
  36. Habib, 2021, Progression of myocardial fibrosis in hypertrophic cardiomyopathy: A cardiac magnetic resonance study, J Am Coll Cardiol Img, 14, 947, 10.1016/j.jcmg.2020.09.037 · DOI
  37. Raja, 2018, Prevance and progression of late gadolinium enhancement in children and adolscents with hypertrophic cardiomyopathy, Circulation, 138, 782, 10.1161/CIRCULATIONAHA.117.032966 · DOI
  38. Maron, 1995, Cardiac disease in young trained athletes. Insights into methods for distinguishing athlete’s heart from structural heart disease with particular emphasis on hypertrophic cardiomyopathy, Circulation, 91, 1596, 10.1161/01.CIR.91.5.1596 · DOI
  39. Cirino, 2017, Role of genetic testing in inherited cardiovascular disease: a review, JAMA Cardiol, 2, 1153, 10.1001/jamacardio.2017.2352 · DOI
  40. Burke, 2016, Clinical and mechanistic insights into the genetics of cardiomyopathy, J Am Coll Cardiol, 68, 2871, 10.1016/j.jacc.2016.08.079 · DOI
  41. Maron, 2012, Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives, J Am Coll Cardiol, 60, 705, 10.1016/j.jacc.2012.02.068 · DOI
  42. Jensen, 2013, Penetrance of hypertrophic cardiomyopathy in children and adolscents: a 12-year follow-up study of clinical screening and predictive genetic testing, Circulation, 127, 48, 10.1161/CIRCULATIONAHA.111.090514 · DOI
  43. Lorenzi, 2020, Penetrance of hypertrophic cardiomyopathy in sarcomere protein mutation carriers, J Am Coll Cardiol, 76, 550, 10.1016/j.jacc.2020.06.011 · DOI
  44. Wong, 2019, Perceptions of genetic variant reclassification in patients with inherited cardiac disease, Eur J Hum Genet, 27, 1134, 10.1038/s41431-019-0377-6 · DOI
  45. Ingles, 2019, Evaluating the clinical validity of hypertrophic cardiomyopathy genes, Circ Genom Precis Med, 12, 10.1161/CIRCGEN.119.002460 · DOI
  46. Maron, 2019, Moving beyond the sarcomere to explain heterogeneity in hypertrophic cardiomyopathy: JACC Review Topic of the Week, J Am Coll Cardiol, 73, 1978, 10.1016/j.jacc.2019.01.061 · DOI
  47. Kapplinger, 2014, Distinguishing hypertrophic cardiomyopathy from background genetic noise, J Cardiovasc Transl Res, 7, 347, 10.1007/s12265-014-9542-z · DOI
  48. Ho, 2018, Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRE), Circulation, 138, 1387, 10.1161/CIRCULATIONAHA.117.033200 · DOI · Paper page
  49. deMarvao, 2021, Phenotypic expression and outcomes in individuals with rare genetic variants of hypertrophic cardiomyopathy, J Am Coll Cardiol, 78, 1097, 10.1016/j.jacc.2021.07.017 · DOI
  50. Bos, 2014, Characterization of a phenotype-based genetic test prediction score for unrelated patients with hypertrophic cardiomyopathy, Mayo Clin Proc, 89, 727, 10.1016/j.mayocp.2014.01.025 · DOI
  51. Gruner, 2013, Toronto hypertrophic cardiomyopathy genotype score for prediction of a positive genotype in hypertrophic cardiomyopathy, Circ Cardiovasc Genet, 6, 19, 10.1161/CIRCGENETICS.112.963363 · DOI
  52. Bonaventura, 2019, The utility of the Mayo Score for predicting the yield of genetic testing in patients with hypertrophic cardiomyopathy, Arch Med Sci, 15, 641, 10.5114/aoms.2018.78767 · DOI
  53. Hathaway, 2021, Diagnostic yield of genetic testing in a heterogeneous cohort of 1376 HCM patients, BMC Cardiovasc Discord, 121
  54. Maron, 2021, Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes, Nat Commun, 12, 873, 10.1038/s41467-021-21146-y · DOI
  55. Toepfer, 2020, Myosin sequestration regulates sarcomere function, cardiomyocyte energetics and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy, Circulation, 141, 828, 10.1161/CIRCULATIONAHA.119.042339 · DOI
  56. Maron, 2009, Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy, JAMA, 301, 1253, 10.1001/jama.2009.371 · DOI
  57. Maron, 2004, Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy, J Am Coll Cardiol, 44, 2125, 10.1016/j.jacc.2004.08.052 · DOI
  58. Panza, 1989, Relation of electrocardiographic abnormalities to evolving left ventricular hypertrophy abnormalities to evolving left ventricular hypertrophy in hypertrophic cardiomyopathy during childhood, Am J Cardiol, 63, 1258, 10.1016/0002-9149(89)90187-2 · DOI
  59. Norrish, 2019, Yield of clinical screening for hypertrophic cardiomyopathy in child first-degree relatives, Circulation, 140, 184, 10.1161/CIRCULATIONAHA.118.038846 · DOI
  60. Maron, 2011, Onset of apical hypertrophic cardiomyopathy in adulthood, Am J Cardiol, 108, 1783, 10.1016/j.amjcard.2011.07.048 · DOI
  61. Ingles, 2017, Nonfamilial hypertrophic cardiomyopathy: prevalence, natural history, and clinical implications, Circ Cardiovasc Genet, 10, 10.1161/CIRCGENETICS.116.001620 · DOI
  62. Maron, 2016, Demographics and epidemiology of sudden deaths in young competitive athletes: From the United States National Registry, Am J Med, 129, 1170, 10.1016/j.amjmed.2016.02.031 · DOI
  63. Maron, 2015, Historical perspectives on sudden deaths in young athletes with evolution over 35 years, Am J Cardiol, 116, 1461, 10.1016/j.amjcard.2015.07.072 · DOI
  64. Maron, 2015, Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis, J Am Coll Cardiol, 66, 2362, 10.1016/j.jacc.2015.09.035 · DOI
  65. Thiene, 2019, Structurally normal hearts are uncommonly associated with sudden deaths in athletes and young people, J Am Coll Cardiol, 73, 3031, 10.1016/j.jacc.2019.03.497 · DOI
  66. Bagnall, 2016, A prospective study of sudden cardiac death among children and young adults, N Engl J Med, 374, 2441, 10.1056/NEJMoa1510687 · DOI
  67. Weissler-Snir, 2019, Hypertrophic cardiomyopathy-related sudden cardiac death in young people in Ontario, Circulation, 140, 1706, 10.1161/CIRCULATIONAHA.119.040271 · DOI
  68. Maron, 2020, Hypertrophic cardiomyopathy and sudden death initially identified at autopsy, Am J Cardiol, 127, 139, 10.1016/j.amjcard.2020.04.021 · DOI
  69. Maron, 2005, 36th Bethesda Conference: eligibility recommendations for competitive athletes with cardiovascular abnormalities, J Am Coll Cardiol, 45, 1312, 10.1016/j.jacc.2005.02.006 · DOI · Paper page
  70. Maron, 2006, Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction, Circulation, 114, 2232, 10.1161/CIRCULATIONAHA.106.644682 · DOI
  71. Pelliccia, 2021, 2020 ESC guidelines on sports cardiology and exercise in patients with cardiovascular disease, Rev Esp Cardiol, 74, 545
  72. Maron, 2017, Shared decision-making in HCM, Nat Rev Cardiol, 14, 125, 10.1038/nrcardio.2017.6 · DOI
  73. Maron, 1998, Competitive athletes with cardiovascular disease-the case of Nicholas Knapp, N Engl J Med, 339, 1632, 10.1056/NEJM199811263392211 · DOI
  74. Saberi, 2017, Effects of moderate-intensity exercise training on peak oxygen consumption in patients with hypertrophic cardiomyopathy: A randomized clinical trial, JAMA, 317, 1349, 10.1001/jama.2017.2503 · DOI · Paper page
  75. Maron, 2018, Longevity in elite athletes: The first 4-minute milers, Lancet, 392, 913, 10.1016/S0140-6736(18)31825-7 · DOI

Cited by

Sorted by citations

Metadata

Authors
Maron, B. J., Desai, M. Y., Nishimura, R. A., Spirito, P., Rakowski, H., Towbin, J. A., Rowin, E. J., Maron, M. S., & Sherrid, M. V.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2022-02
Volume
79
Issue
4
Pages
372-389
ISSN
0735-1097
DOI
10.1016/j.jacc.2021.12.002
Cited by
637
References
2
Language
en
Licence
Funders
  • Pfizer
  • Takeda Pharmaceuticals U.S.A.

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review